Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Does high transferrin saturation increase non-transferrin-bound iron and oxidative exposure?

High transferrin saturation can allow iron to circulate as non-transferrin-bound or labile iron, increasing oxidative exposure.

PlausibleJuly 8, 202617 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

When transferrin saturation is high, more circulating iron can appear as labile or non-transferrin-bound iron, increasing oxidative exposure.

laying out figure…
0 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says that once transferrin binding capacity is exceeded, surplus iron is less safely sequestered and can appear in more reactive circulating forms. The mechanism frame links this shift to redox-active iron chemistry, lipid peroxidation, and downstream mitochondrial injury. It also associates the oxidative process with biomarkers such as F2-isoprostanes.

Verified conclusion

Under physiological conditions, transferrin saturation (TSAT) is maintained between 20% and 45% to keep iron safely bound and sequestered. When systemic iron levels overwhelm transferrin binding capacity, surplus iron circulates as non-transferrin-bound iron (NTBI) and its highly toxic subfraction, labile plasma iron (LPI).

Thresholds of NTBI and LPI Generation

  • Pathological thresholds: NTBI concentrations rise sharply once TSAT exceeds approximately 70%, below which it is only sporadically detected.
  • LPI emergence: The highly reactive LPI fraction requires a higher threshold, appearing robustly when TSAT exceeds 80% to 90%. When TSAT exceeds 90%, both species are almost universally detectable.
  • Low-affinity binding: When transferrin is saturated, excess iron binds weakly to low-molecular-weight ligands like citrate, acetate, and albumin, forming these circulating species.

Molecular Mechanisms of Oxidative Damage

  • Fenton chemistry: LPI is highly redox-active and directly catalyzes Fenton and Haber-Weiss-type reactions with hydrogen peroxide. This process generates highly reactive hydroxyl radicals and other reactive oxygen species (ROS).
  • Mitochondrial and tissue injury: Membrane-permeant LPI enters cells through unregulated pathways, accumulating in vulnerable tissues like the heart and liver. Within cells, it targets mitochondria, causing membrane injury, impaired electron transport, reduced ATP production, and mitochondrial DNA damage.
  • Lipid peroxidation: Cellular ROS drive the non-enzymatic peroxidation of membrane polyunsaturated fatty acids, depleting protective antioxidants like glutathione. This process yields F2-isoprostanes—a gold-standard biomarker of systemic oxidative stress—and can ultimately trigger ferroptotic cell death.

Bottom line

  • Transferrin saturation exceeding 70% (for NTBI) and 90% (for LPI) directly causes the appearance of highly redox-active, unshielded iron species that catalyze Fenton chemistry, driving widespread lipid peroxidation, mitochondrial dysfunction, and oxidative tissue damage.

References

  1. Second international round robin for the quantification of serum non ... — haematologica.org ↗
  2. [PDF] LPI NTBI - KDIGO — kdigo.org ↗
  3. Labile plasma iron levels predict survival in patients with lower-risk ... — pmc.ncbi.nlm.nih.gov ↗
  4. Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay — pmc.ncbi.nlm.nih.gov ↗
  5. Second international round robin for the quantification of serum non ... — haematologica.org ↗
  6. Non Transferrin Bound Iron: Nature, Manifestations and Analytical ... — pmc.ncbi.nlm.nih.gov ↗
  7. Oxidative stress and labile plasmatic iron in anemic patients ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  8. Iron and oxidizing species in oxidative stress and Alzheimer's disease — pmc.ncbi.nlm.nih.gov ↗
  9. Changes in parameters of oxidative stress and free iron biomarkers ... — pmc.ncbi.nlm.nih.gov ↗
  10. Full article: Labile plasma iron, more practical and more sensitive to ... — tandfonline.com ↗
  11. Emerging mechanisms of lipid peroxidation in regulated cell death ... — nature.com ↗
  12. Formation of F2-Isoprostanes During Oxidation of Human Low ... — ahajournals.org ↗
  13. F2-Isoprostane/Creatinine Ratio | Test Detail | Quest Diagnostics — testdirectory.questdiagnostics.com ↗
  14. Isoprostanes | Eicosanoid Core Laboratory — vumc.org ↗
  15. The role of mitochondria in iron overload-induced damage — pmc.ncbi.nlm.nih.gov ↗
  16. Mitochondrial iron overload: causes and consequences. — pmc.ncbi.nlm.nih.gov ↗
  17. Exploring the Impact of Iron Overload on Mitochondrial DNA in β ... — xiahepublishing.com ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesDoes the MTHFR rs1801131 A1298C variant mildly reduce enzyme activity and have a smaller homocysteine effect than C677T?→Plausible3 sourcesIs TMAO formed from gut microbial conversion of choline and carnitine followed by liver oxidation?→